WINNERSH, England, Sept. 12 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER, Nasdaq: VNLS) today announced its interim results for the six months ended 30 June 2006. Simon Sturge, chief executive officer of Vernalis, commented: “Vernalis is continuing to show substantial progress toward becoming a self-funding, sustainable R&D driven commercial business. Establishing our U.S. operation with the successful launch of Apokyn® and completing the Frova® clinical trials for the short-term prevention of menstrual migraine were significant achievements. The second half of 2006 is expected to have substantial news flow as we progress our drug candidates through the clinic and boost our product revenues.”
